Additional Value of Pertechnetate Scintigraphy to American College of Radiology Thyroid Imaging Reporting and Data Systems and European Thyroid Imaging Reporting and Data Systems for Thyroid Nodule Classification in Euthyroid Patients
2024

Improving Thyroid Nodule Diagnosis with Scintigraphy

Sample size: 208 publication 10 minutes Evidence: moderate

Author Information

Author(s): Sollmann Lea, Eveslage Maria, Danzer Moritz Fabian, Schäfers Michael, Heitplatz Barbara, Conrad Elke, Hescheler Daniel, Riemann Burkhard, Noto Benjamin, Jarzab Barbara, Li Wen, Magbanua Mark Jesus M.

Primary Institution: University of Münster

Hypothesis

Does integrating pertechnetate scintigraphy with TIRADS improve the diagnostic accuracy for thyroid nodules in euthyroid patients?

Conclusion

Integrating thyroid scintigraphy with ACR- or EU-TIRADS moderately improves diagnostic performance for thyroid nodules.

Supporting Evidence

  • Thyroid nodules are common and often benign, but can be malignant in up to 15% of cases.
  • Thyroid scintigraphy provides functional status of nodules, which can aid in diagnosis.
  • The study found that integrating scintigraphy improved diagnostic accuracy for nodules with intermediate malignancy risk.
  • ACR-TIRADS outperformed EU-TIRADS in diagnostic performance.
  • Further research is needed to validate the clinical implications of these findings.

Takeaway

This study found that using a special scan called scintigraphy along with standard ultrasound methods can help doctors better understand if thyroid nodules are cancerous.

Methodology

The study analyzed the diagnostic performance of ACR-TIRADS, EU-TIRADS, and scintigraphy on 322 nodules in 208 euthyroid patients using histopathology as a reference.

Potential Biases

Potential bias from merging two distinct patient groups and the high prevalence of malignant nodules in the study population.

Limitations

The retrospective design and variability in imaging quality due to different institutions may introduce bias.

Participant Demographics

68.9% female, median age 47 years.

Statistical Information

P-Value

0.039

Confidence Interval

95% CI: 0.55–0.66

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/cancers16244184

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication